Live Breaking News & Updates on Hereditary Spastic Paraplegias

Stay updated with breaking news from Hereditary spastic paraplegias. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dynacure to Present Preclinical Data on Disease Progression Modelling and ASO-Mediated Dynamin 2 Knockdown at World Muscle Society (WMS) Meeting

Dynacure to Present Preclinical Data on Disease Progression Modelling and ASO-Mediated Dynamin 2 Knockdown at World Muscle Society (WMS) Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Centronuclear Myopathies , Belinda Cowling , Neuromuscul Disord , European Union , European Medicines Agency , World Muscle Society , Ionis Pharmaceuticals , Annual Congress , Chief Scientific Officer Belinda Cowling , Investigational New Drug , Ionis Pharmaceutical , Orphan Drug , Hereditary Spastic Paraplegias , ஒன்றுபட்டது மாநிலங்களில் , பெலிண்டா கோலிங் , ஐரோப்பிய தொழிற்சங்கம் , உலகம் தசை சமூகம் , ஆண்டு காங்கிரஸ் , ஆர்ஃபந் மருந்து ,

Dynacure Announces FDA Acceptance of Investigational New Drug Application for DYN101 for Myotubular and Centronuclear Myopathies

/PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare. ....

United States , Stephane Van Rooijen , Centronuclear Myopathies , Neuromuscul Disord , European Union , European Medicines Agency , Drug Administration , Ionis Pharmaceuticals , Investigational New Drug , Leen Thielemans , Chief Development Officer , Chief Executive Officer , Ionis Pharmaceutical , Orphan Drug , Hereditary Spastic Paraplegias , Health Care Amp Hospitals , Medical Pharmaceuticals , New Products Amp Services , Clinical Trials Amp Medical Discoveries , Fda Approval , ஒன்றுபட்டது மாநிலங்களில் , ஐரோப்பிய தொழிற்சங்கம் , தலைமை வளர்ச்சி அதிகாரி , தலைமை நிர்வாகி அதிகாரி , ஆர்ஃபந் மருந்து , ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் ,

Dynacure Recognizes Rare Disease Day 2021

Dynacure Recognizes Rare Disease Day 2021
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United States , Stephane Van Rooijen , Centronuclear Myopathies , Holger Fischer , Prnewswire Dynacure , Neuromuscul Disord , European Union , Ionis Pharmaceuticals , Rare Disease Day , Centronuclear Myopathy , Dynacure Chief Executive Officer Stephane , Disease Day , Hereditary Spastic Paraplegias , ஒன்றுபட்டது மாநிலங்களில் , ஐரோப்பிய தொழிற்சங்கம் , ரேர் நோய் நாள் , சிஇஎன்டிஆர்ஓஎன்யுவ்சிஎல்இஏஆர் மயோபதி , நோய் நாள் ,

Dynacure Announces Issuance of U.S. Patent for DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)

Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 26, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. US 10, 865, 414 related to DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein (DNM2), for the treatment of Myotubular and Centronuclear Myopathies (CNM). The U.S. patent is part of a patent family, exclusively licensed from Ionis Pharmaceuticals, which covers modulators of DNM2 expression. This patent family includes one additional U.S. pending application and one European application and 18 other foreign pending applications (Australia, Brazil, Canada, Chili, China, Colombia, Israel, India, Japan, Korea, Mexico, Malaysia, New-Zealand ....

United States , South Africa , Centronuclear Myopathies , Frederic Legros , Neuromuscul Disord , Trademark Office , European Union , Tekla Capital Management , Ionis Pharmaceuticals , Chief Operating Officer , Ionis Pharmaceutical , Orphan Drug , Hereditary Spastic Paraplegias , Andera Partners , Bpifrance Large Venture , Fonds Bioth , Maladies Rares , Kurma Partners , Perceptive Advisors , ஒன்றுபட்டது மாநிலங்களில் , ஃப்ரெடரிக் லெக்ரோஸ் , முத்திரை அலுவலகம் , ஐரோப்பிய தொழிற்சங்கம் , தெக்கில மூலதனம் மேலாண்மை , தலைமை இயங்குகிறது அதிகாரி , ஆர்ஃபந் மருந்து ,

Dynacure Announces Appointment of Jean M. Franchi to its Board of Directors

Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 21, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. Franchi to its Board of Directors. Ms. Franchi is an experienced board member, finance executive and operational leader with more than three decades of experience in the life sciences industry.
I am very pleased to welcome Jean to the Dynacure Board, said Georges Gemayel, Chairman of the Board of Directors of Dynacure. Jean will be a valuable addition to our team, bringing expertise in financial and long-term strategies, and we look forward to her guidance. ....

United States , Georges Gemayel , Stephane Van Rooijen , Jeanm Franchi , Centronuclear Myopathies , Hofstra University , Merrimack Pharmaceuticals , Tekla Capital Management , Dimension Therapeutics Inc , Business Administration , Ionis Pharmaceuticals , Dynacure Board , Chief Financial Officer , Good Start Genetics , Dimension Therapeutics , Senior Vice President , Corporate Finance , Chief Executive Officer , Hereditary Spastic Paraplegias , Andera Partners , Bpifrance Large Venture , Fonds Bioth , Maladies Rares , Kurma Partners , Perceptive Advisors , ஒன்றுபட்டது மாநிலங்களில் ,